PYPD

PolyPid Ltd.

5.38 USD

Last updated Sep 5, 11:22 UTC

Yesterday HIGH

$5.44

Yesterday LOW

$5.21

52w HIGH

$5.73

52w LOW

$3.06

EPS

-0.35

PE

-15.37

Next Earnings

Nov 11, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

PolyPid Ltd. stock is up 11.85% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 6 September’s closed higher than August. In the last 2 Unusual Options Trades, there were 2 CALLs.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

18 Aug 13:52	19 Feb, 2027	5.00	CALL	200	74
19 Aug 13:54	19 Feb, 2027	5.00	CALL	200	446

Advanced Data Unlock

Benzinga Insights

Tue Jul 21, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's regular session. The company's market cap stands at $36.8 million. Wellgistics Health (NASDAQ:WGRX) shares increased
Benzinga Newsdesk

Tue Jul 21, 2026

HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $13 price target.
Benzinga Newsdesk

Tue Jul 21, 2026

PolyPid shares are trading lower. The company announced it has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for the commercialization of D-PLEX100.
Benzinga Newsdesk

Tue Jul 21, 2026

PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront Payment

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has
Benzinga Newsdesk

Mon Jun 1, 2026

PolyPid Completes Its New Drug Application Submission On Rolling Review Basis Top FDA For D-PLEX100 To Prevent Surgical Site Infections

PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced the
Benzinga Insights

Wed May 13, 2026

PolyPid Q1 2026 Earnings Call: Complete Transcript
Benzinga Newsdesk

Wed May 13, 2026

PolyPid Q1 EPS $(0.35) Beats $(0.43) Estimate
Benzinga Insights

Wed May 13, 2026

Earnings Scheduled For May 13, 2026
Benzinga Newsdesk

Tue Apr 28, 2026

PolyPid To Present ASEPSIS Analysis Data From Its Phase 3 SHIELD II Study Of D-PLEX At 5th Annual Meeting Of The Surgical Infection Society

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that
Benzinga Newsdesk

Mon Apr 13, 2026

PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that